Services

Inquiry and ordering

Name*
Phone*
Email*
Product*
Content*

Nuclide Nucleic Acid Aptamer Screening Service

In recent years, radionuclide conjugated drugs have become a hot topic in the field of targeted drug development and a key direction in this area due to their therapeutic potential in oncology and their ability to integrate diagnosis and treatment. However, the methods for coupling radionuclides to target molecules have certain limitations: radionuclides must either be indirectly coupled to the target small molecule via a “bridge” such as a chelating agent, or directly covalently linked to the target small molecule through a chemical reaction. Currently, neither of these two radionuclide-coupling methods is universally applicable; therefore, the development of new radionuclide-coupling “bridges” is of critical importance.

TekBiotech has established a nucleic acid aptamer library with a capacity on the order of 10^14, which is theoretically sufficient to meet the screening requirements for nucleic acid aptamers targeting any target; the affinity of candidate aptamer sequences can reach the nM–pM range. TekBiotech is committed to providing clients with high-affinity, high-specificity nucleic acid aptamer screening services. The company also offers complementary downstream services, including aptamer synthesis, modification, and affinity detection, to meet the needs of “bridge” development for radionuclide conjugation. These services support clients’ development of targeted radiopharmaceuticals and play a significant role in the creation of new radiopharmaceuticals that integrate diagnosis and therapy.

Figure 1- Principle of Developing Nuclide-Coupled “Bridges”.png

Figure 1: Principle of Developing Nuclide-Coupled “Bridges”

TekBiotech has many years of project experience and expertise in nucleic acid aptamer screening (SELEX technology). For small-molecule targets such as radionuclides, TekBiotech’s scientists have developed a screening system based on conformational changes in nucleic acid aptamers. Using this system, TekBiotech is able to provide clients with high-quality radionuclide nucleic acid aptamer screening services.

█ Nuclide Nucleic Acid Aptamer Screening Service（SELEX Screening Technology Services）

Nucleic acid aptamer screening refers to a technique based on the principle of Systematic Evolution of Ligands by Exponential Enrichment (SELEX), in which target oligonucleotide fragments (DNA or RNA fragments) are obtained from a nucleic acid aptamer library through incubation of the target molecule with the library, electrophoretic separation, and amplification.

For nuclear targets, TekBiotech redesigned the nucleic acid aptamer library by incorporating conformational changes and optoelectronic reporter systems (primarily by redesigning the sequence length of the saturation mutation library and the homologous arms at both ends of the saturation mutation region), and ultimately immobilized the library for subsequent nuclide screening. The nuclide screening steps are shown in Figure 2:

Figure 2- Procedure for SELEX-Based Screening of Nucleic Acid Adaptors Based on Conformational Changes.png

Figure 2: Procedure for SELEX-Based Screening of Nucleic Acid Adaptors Based on Conformational Changes

TekBiotech offers a wide variety of aptamer screening methods (e.g., magnetic bead-SELEX, cell-SELEX, CE-SELEX, etc.), each designed for screening different types of antigen-targeting aptamers. Leveraging its proprietary nucleic acid aptamer screening technology platform, TekBiotech conducts a detailed assessment tailored to each client’s specific requirements. The core of the nucleic acid aptamer screening process lies in the synergy between SELEX technology and the screening protocol. This integrated system facilitates the identification of nucleic acid molecules that bind with high affinity to specific targets from a vast library of nucleic acid sequences through iterative selection and amplification steps. Clients need only provide basic information about the target molecule; our scientists will then design a tailored protocol based on this information to deliver high-quality nucleic acid aptamers.